DE69812343D1 - Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff - Google Patents

Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff

Info

Publication number
DE69812343D1
DE69812343D1 DE69812343T DE69812343T DE69812343D1 DE 69812343 D1 DE69812343 D1 DE 69812343D1 DE 69812343 T DE69812343 T DE 69812343T DE 69812343 T DE69812343 T DE 69812343T DE 69812343 D1 DE69812343 D1 DE 69812343D1
Authority
DE
Germany
Prior art keywords
sae
pharmaceutical formulations
sulphoalkylethercyclodextrin
active substance
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69812343T
Other languages
English (en)
Other versions
DE69812343T2 (de
Inventor
K Stella
James Macginity
A Rajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Publication of DE69812343D1 publication Critical patent/DE69812343D1/de
Application granted granted Critical
Publication of DE69812343T2 publication Critical patent/DE69812343T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DE69812343T 1997-05-05 1998-04-20 Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff Expired - Lifetime DE69812343T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/851,006 US5874418A (en) 1997-05-05 1997-05-05 Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US851006 1997-05-05
PCT/US1998/008221 WO1998050077A1 (en) 1997-05-05 1998-04-20 Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent

Publications (2)

Publication Number Publication Date
DE69812343D1 true DE69812343D1 (de) 2003-04-24
DE69812343T2 DE69812343T2 (de) 2004-04-01

Family

ID=25309709

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812343T Expired - Lifetime DE69812343T2 (de) 1997-05-05 1998-04-20 Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff

Country Status (10)

Country Link
US (1) US5874418A (de)
EP (1) EP0980262B1 (de)
JP (1) JP3745382B2 (de)
KR (1) KR100378031B1 (de)
AT (1) ATE234634T1 (de)
AU (1) AU729671B2 (de)
CA (1) CA2289202C (de)
DE (1) DE69812343T2 (de)
ES (1) ES2190075T3 (de)
WO (1) WO1998050077A1 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU775037B2 (en) * 1998-12-09 2004-07-15 Eli Lilly And Company Pellet implant system
DE59804823D1 (de) * 1997-09-25 2002-08-22 Bayer Ag Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
KR100569763B1 (ko) * 1997-10-03 2006-04-11 워너-램버트 캄파니 엘엘씨 니트로글리세린 압축 정제 및 그의 제조 방법
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1207852A4 (de) * 1999-09-02 2009-11-11 Nostrum Pharmaceuticals Inc Orale darreichung mit gesteuerter freisetzung zur oralen verabreichung
DE19941769A1 (de) * 1999-09-02 2001-03-08 Beiersdorf Ag Wirkstoffkombinationen bzw. Addukte aus Biotin und/oder Biotinderivaten und Cyclodextrinen und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen
US6346231B1 (en) * 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US6294013B1 (en) * 1999-12-08 2001-09-25 Sun Chemical Corporation Polysaccharide pigment dispersions
CA2726789A1 (en) * 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
US20030148996A1 (en) * 2000-03-31 2003-08-07 Joseph Rubinfeld Camptothecin complexes
DE60128215T2 (de) * 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
US6953586B1 (en) 2000-06-08 2005-10-11 Ivy Animal Health, Inc. Growth promoting pharmaceutical implant
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
AU2002241823A1 (en) * 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
IN190699B (de) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
DE10114245A1 (de) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Herstellung und Verwendung einer Antibiotikum-/Antibiotika-Zubereitung
DE10114364A1 (de) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Verfahren zur Herstellung von antibiotischen Kompositen
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EP1461044A4 (de) * 2001-12-03 2007-06-13 Novacea Inc Pharmazeutische zusammensetzungen mit aktiven vitamin-d-verbindungen
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
CA2473991C (en) 2002-02-01 2009-09-15 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
JP2005521690A (ja) * 2002-02-22 2005-07-21 ファルマシア・コーポレーション ゴム系を含む眼科用製剤
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050026849A1 (en) * 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
EP1730751B1 (de) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Magnetoresistives medium
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
AU2015255259B2 (en) * 2004-04-23 2017-07-27 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
SI2708225T1 (sl) * 2004-04-23 2019-05-31 Cydex Pharmaceuticals, Inc. Formulacija DPI, ki vsebuje sulfoalkil eter ciklodekstrin
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
DK2030981T3 (da) * 2004-05-10 2014-10-13 Onyx Therapeutics Inc Forbindelser til proteasom-enzymhæmning
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US20080075784A1 (en) * 2004-07-22 2008-03-27 Pfizer Inc. Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
KR101299821B1 (ko) * 2004-12-07 2013-09-03 프로테올릭스, 인코퍼레이티드 프로테아좀 저해를 위한 조성물
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060183725A1 (en) * 2005-02-15 2006-08-17 Thomas Graeser Pharmaceutical preparation for oral contraception
AU2011204957B2 (en) * 2005-10-26 2013-12-05 Cydex Pharmaceuticals, Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
ES2364491T5 (es) 2005-10-26 2015-02-19 Cydex Pharmaceuticals, Inc. Composiciones de sulfoalquiléter ciclodextrina y métodos de preparación de las mismas
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2623113B1 (de) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Verbindung zur Enzymhemmung
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
CA2634413A1 (en) * 2005-12-20 2007-07-05 Tika Laekemedel Ab Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
US20080069889A1 (en) * 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
JP5226679B2 (ja) 2006-06-19 2013-07-03 プロテオリックス, インコーポレイテッド 酵素阻害のための化合物
US8639782B2 (en) 2006-08-23 2014-01-28 Ebay, Inc. Method and system for sharing metadata between interfaces
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20080194519A1 (en) * 2006-09-15 2008-08-14 Regents Of The University Of Minnesota Topiramate compositions and methods for their use
JP2010527285A (ja) * 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
US8343995B2 (en) 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US20110177161A1 (en) * 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
US10406105B2 (en) * 2007-06-06 2019-09-10 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TWI501773B (zh) 2007-10-04 2015-10-01 Onyx Therapeutics Inc 結晶肽環氧酮蛋白酶抑制劑以及胺基酸酮環氧化物之合成
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
WO2010048298A1 (en) 2008-10-21 2010-04-29 Proteolix, Inc. Combination therapy with peptide epoxyketones
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
MA32931B1 (fr) 2008-11-15 2012-01-02 Rib X Pharmaceuticals Inc Compositions antimicrobiennes
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
CN102458114A (zh) 2009-05-29 2012-05-16 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
WO2010147978A1 (en) 2009-06-16 2010-12-23 Pfizer Inc. Dosage forms of apixaban
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
EP2498793B1 (de) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib zur verwendung in der metastasensuppression
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20130203721A1 (en) 2010-02-22 2013-08-08 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
AU2011245630B2 (en) 2010-04-07 2014-07-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
EP2621475A1 (de) 2010-10-02 2013-08-07 Link Research&Grants Corporation Behandlung von tinnitus und zugehörigen dysfunktionen des gehörs
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
EP2758052B9 (de) 2011-09-18 2019-03-27 Euro-Celtique S.A. HDAC-Hemmer-Cyclopolysaccharidzusammensetzung
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
AU2013334921B2 (en) 2012-10-22 2018-03-29 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
NZ725354A (en) 2014-06-18 2018-05-25 Elanco Us Inc Transdermal formulations of pergolide and uses thereof
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CA2974123C (en) 2015-02-02 2023-08-01 Mei Pharma, Inc. Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy
EP3939582A1 (de) 2015-03-19 2022-01-19 Cydex Pharmaceuticals, Inc. Zusammensetzungen mit silymarin und sulfoalkylethercyclodextrin und verfahren zur verwendung davon
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
CN110022857A (zh) 2016-11-18 2019-07-16 艾库里斯抗感染治疗有限公司 基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
KR20190141244A (ko) 2017-05-03 2019-12-23 사이덱스 파마슈티칼스, 인크. 사이클로덱스트린 및 부설판을 함유하는 조성물
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
WO2019051477A1 (en) 2017-09-11 2019-03-14 Sage Therapeutics, Inc. METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION
CA3149914A1 (en) 2019-08-06 2021-02-11 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
WO2021255291A1 (en) 2020-06-18 2021-12-23 The University Of Bristol Fatty acid complexes of coronavirus spike protein and their use
EP4243805A1 (de) 2020-08-07 2023-09-20 Gbiotech S.À.R.L. Kombinationstherapien zur behandlung von coronavirusinfektion
CN114128914B (zh) * 2021-12-02 2023-02-10 云南中烟工业有限责任公司 一种包合物、其制备方法及用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (de) * 1970-06-10 1975-02-04
JPS57182301A (en) * 1981-01-23 1982-11-10 Wellcome Found Composite body of sugar-containing compound and cycloamlose and manufacture
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
CA2289202A1 (en) 1998-11-12
JP3745382B2 (ja) 2006-02-15
AU7153598A (en) 1998-11-27
AU729671B2 (en) 2001-02-08
KR100378031B1 (ko) 2003-04-16
US5874418A (en) 1999-02-23
ES2190075T3 (es) 2003-07-16
DE69812343T2 (de) 2004-04-01
JP2002503267A (ja) 2002-01-29
EP0980262B1 (de) 2003-03-19
CA2289202C (en) 2005-03-15
WO1998050077A1 (en) 1998-11-12
ATE234634T1 (de) 2003-04-15
EP0980262A1 (de) 2000-02-23
KR20010012233A (ko) 2001-02-15

Similar Documents

Publication Publication Date Title
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
FR2789079B3 (fr) Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
HUP0004924A2 (hu) Ciklodextrineket tartalmazó gyógyászati készítmények
ATE460921T1 (de) Medikamenthaltige zusammensetzung in aerosolform
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
CY1107305T1 (el) Νανοσωματιδιακες συνθεσεις στερεης μορφης
DE69940769D1 (de) Orale flüssige zusammensetzungen
DE60108154D1 (de) Pharmazeutische Zubereitungen enthaltend Clavulansäure
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ATE66605T1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
DE50112438D1 (de) Zahnpflegemittel in portionskapseln
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
FR2789078B3 (fr) Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
MY152490A (en) New oral formulation
DE60013849D1 (de) Ascidideminderivate und ihre therapeutische verwendung

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CYDEX PHARMACEUTICALS, INC., LENEXA, KAN., US